Document:

EX-10.2

 Exhibit 10.2 

SUPPLEMENT TO JOINDER AGREEMENT 

This Supplement to Joinder Agreement (the “Supplement”) is made and dated as of June 23, 2015, and is entered into by and
between Zosano Pharma Corporation, a Delaware corporation (“Parent”), HERCULES CAPITAL FUNDING TRUST 2014-1, a Delaware statutory trust (“Trust”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation
(“HTGC”, and collectively with Trust, the “Lender”). 
 RECITALS 

A. Parent previously executed and delivered to HTGC a Joinder Agreement dated as of June 3, 2014 (the “Joinder Agreement”), in
connection that certain Loan and Security Agreement dated as of June 3, 2014, by and among ZP Opco, Inc. (f/k/a Zosano Pharma, Inc.) (“Borrower”) and HTGC, as it may be amended, amended and restated, supplemented or other otherwise
modified from time to time (the “Loan Agreement”); 
 B. Trust succeeded to certain rights of HTGC under the Loan Agreement; 

C. Borrower desires to amend the Loan Agreement to increase the amount of funds available to it and to change other terms as provided in that
certain First Amendment to Loan and Security Agreement dated even date herewith (the “First Amendment”); 
 D. In connection with
the First Amendment, Lender requires that Parent agree to the terms and conditions of the First Amendment, provide this Supplement and issue HTGC a warrant as required in the First Amendment; 

B. Parent acknowledges and agrees that it will benefit both directly and indirectly from Company’s execution of the First Amendment and
the other agreements executed and delivered in connection therewith; 
 AGREEMENT 

NOW THEREFORE, Parent and Lender agree as follows: 
  

	1.	The recitals set forth above are incorporated into and made part of this Supplement to Joinder Agreement. Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement. 

 

	2.	By signing this Supplement to Joinder Agreement, Parent shall be bound by the terms and conditions of the First Amendment the same as if it were the Borrower (as defined in the First Amendment) under the First
Amendment, mutatis mutandis, provided however, that Lender shall not have any duties, responsibilities or obligations to Parent arising under or related to the First Amendment, or the other agreements executed and delivered in connection
therewith. To the extent that Lender has any duties, responsibilities or obligations arising under or related to the First Amendment or the other agreements executed and delivered in connection therewith, those duties, responsibilities or
obligations shall flow only to Borrower and not to Parent or any other Person or entity. 

  
 1 

	3.	Parent acknowledges that it benefits, both directly and indirectly, from the First Amendment, and hereby waives, for itself and on behalf on any and all successors in interest (including without limitation any assignee
for the benefit of creditors, receiver, bankruptcy trustee or itself as debtor-in-possession under any bankruptcy proceeding) to the fullest extent provided by law, any and all claims, rights or defenses to the enforcement of this Supplement to
Joinder Agreement on the basis that (a) it failed to receive adequate consideration for the execution and delivery of this Supplement to Joinder Agreement or the Warrant issued as required by the First Amendment, or (b) its obligations
under this Supplement to Joinder Agreement or the Warrant issued as required by the First Amendment are avoidable as a fraudulent conveyance. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 2 

 [SIGNATURE PAGE TO SUPPLEMENT TO JOINDER AGREEMENT] 

ZOSANO PHARMA CORPORATION 
  

					
			By:		 /s/ Vikram Lamba

			Name: Vikram Lamba
			Title: CEO
		
			Address:
			Attention: Vikram Lamba
			34790 Ardentech Court
			Fremont, CA 94555
			Facsimile: 510-952-4632
			Telephone: 510-745-1297

 HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

  

					
			By:		 /s/ Ben Bang

			Name: Ben Bang
			Title: Associate General Counsel
		
			Address:
			400 Hamilton Ave., Suite 310
			Palo Alto, CA 94301
			Facsimile: 650-473-9194
			Telephone: 650-289-3060

 HERCULES CAPITAL FUNDING TRUST 2014-1 

 

					
			By:		 /s/ Ben Bang

			Name: Ben Bang
			Title: Associate General Counsel
		
			Address:
			400 Hamilton Ave., Suite 310
			Palo Alto, CA 94301
			Facsimile: 650-473-9194
			Telephone: 650-289-3060

  
 3EX-10.3

 Exhibit 10.3 

THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT
AGREEMENT 
 To Purchase Shares of Common Stock of 

Zosano Pharma Corporation 
 Dated
as of June 23, 2015 (the “Effective Date”) 
 WHEREAS, ZP Opco, Inc., a Delaware corporation (“ZP Opco”), is a wholly-owned
subsidiary of the Company (as defined below); 
 WHEREAS, ZP Opco has entered into a Loan and Security Agreement dated as of June 3, 2014, as amended
pursuant to that certain First Amendment to Loan and Security Agreement dated as of June 23, 2015 (collectively, the “Loan Agreement”) with Hercules Technology Growth Capital, Inc., a Maryland corporation
(“Hercules”) the other lender parties thereto; 
 WHEREAS, the Company desires to grant to Hercules, in consideration for, among other
things, the financial accommodations provided ZP Opco in the Loan Agreement, the right to purchase shares of Company Stock (as defined below) pursuant to this Warrant Agreement (the “Agreement”); 

NOW, THEREFORE, in consideration of Hercules’s executing and delivering the Loan Agreement and providing the financial accommodations contemplated
therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Hercules agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE COMPANY STOCK. 

For value received, the Company hereby grants to Hercules, and Hercules is entitled, upon the terms and subject to the conditions hereinafter set forth, to
subscribe for and purchase, from the Company, an aggregate number of fully paid and non-assessable shares of the Company Stock equal to the quotient derived by dividing (a) the Warrant Amount (defined below) by (b) the Exercise Price
(defined below). As used herein, the following terms shall have the following meanings: 
 “1934 Act” means the Securities
Exchange Act of 1934, as amended. 
 “Act” means the Securities Act of 1933, as amended. 

“Company” means Zosano Pharma Corporation, a Delaware corporation, and any successor or surviving entity that assumes the
obligations of the Company under this Agreement pursuant to Section 8(a). 
 “Charter” means the Company’s
Certificate of Incorporation or other constitutional document, as may be amended from time to time. 
 “Common Stock” means
the Company’s common stock, $0.0001 par value per share. 
 “Company Stock” means Common Stock. 

“Exercise Price” means, subject to adjustment pursuant to Section 8, $7.37 per share. 

“Initial Public Offering” means the initial underwritten public offering of the Company’s Common Stock pursuant to a
registration statement under the Act, which registration statement has been declared effective by the Securities and Exchange Commission (“SEC”). 

 “Marketable Securities” means securities issued by a corporation whose equity
securities are traded on NASDAQ, NYSE or AMEX, which securities have been registered under the Act and can be sold immediately following the closing of a Merger Event regardless of any lock-up or other restriction. 

“Merger Event” means any sale, lease or other transfer of all or substantially all assets of the Company or any merger or
consolidation involving the Company in which the Company is not the surviving entity, or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital stock or other securities or
property of another entity. 
 “Purchase Price” means, with respect to any exercise of this Agreement, an amount equal to
the Exercise Price as of the relevant time multiplied by the number of shares of Company Stock requested to be exercised under this Agreement pursuant to such exercise. 

“Qualified Merger Event” means a Merger Event in which the consideration to be received by holders of Company Stock at the
closing of such Merger Event consists of cash or Marketable Securities (or a combination of cash and Marketable Securities). 
 “Rule
144” means Rule 144 as promulgated by the SEC under the Act. 
 “Warrant Amount” means 300,000. 

SECTION 2. TERM OF THE AGREEMENT. 

(a) Term. Except as otherwise provided for herein, the term of this Agreement and the right to purchase Company Stock as granted herein
(the “Warrant”) shall commence on the Effective Date and shall be exercisable for a period ending upon June 23, 2020. 
 (b)
Early Termination. The Company shall provide written notice to the registered holder of this Agreement of a Qualified Merger Event at least ten days prior to the consummation of the Merger Event. Notice from the Company to the registered
holder of this Agreement of a Qualified Merger Event shall provide detailed information regarding the consideration to be received by holders of Company Stock in connection with such Qualified Merger Event. In the event of a Qualified Merger Event
where the registered holder of this Agreement elects not to exercise its rights under this Agreement to acquire shares of Company Stock in connection with the Qualified Merger Event, then the Company may elect to pay to the registered holder of this
Agreement, at closing of such Qualified Merger Event, an amount in cash equal to one (1) times the aggregate Exercise Price for the number of shares of Company Stock acquirable under this Agreement as of the date of such Qualified Merger Event
(i.e., the Exercise Price per share times the number of shares of Company Stock acquirable under this Agreement as of the date of such Qualified Merger Event) and this Agreement shall be terminated effective upon receipt of such payment, which
payment shall be in complete satisfaction hereof. 
 SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by Hercules, in whole or in part, at any time, or from
time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly
completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three (3) days thereafter, the Company shall instruct its
transfer agent and registrar to issue to Hercules a certificate (or book-entry form equivalent) for the number of shares of Company Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II
(the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future purchases, if any. 
 The Purchase Price
may be paid at Hercules’s election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Company Stock to be exercised under this Agreement and, if

  
 2 

 
applicable, an amended Agreement representing the remaining number of shares purchasable hereunder, as determined below (“Net Issuance”). If Hercules elects the Net Issuance
method, the Company will issue Company Stock in accordance with the following formula: 
  

					
					 X = Y(A-B)

					             A

			
	 Where:
		X =		the number of shares of Company Stock to be issued to Hercules.
			
			Y =		the number of shares of Company Stock requested to be exercised under this Agreement.
			
			A =		the fair market value of one (1) share of Company Stock at the time of issuance of such shares of Company Stock.
			
			B =		the Exercise Price.

 For purposes of the above calculation, current fair market value of Company Stock shall mean with respect to each share of
Company Stock: 
 (i) if the Common Stock is traded on a securities exchange, the fair market value per share shall be deemed
to be the average of the closing prices over a five (5) day period ending three days before the day the current fair market value of the securities is being determined; or 

(ii) if the Common Stock is traded over-the-counter, the fair market value per share shall be deemed to be the average of the
closing bid and asked prices quoted over the five (5) day period ending three days before the day the current fair market value of the securities is being determined; 

(iii) if at any time the Common Stock is not listed on any securities exchange or quoted in the over-the-counter market, the
current fair market value per share of Company Stock shall be the highest price per share which the Company could obtain from a willing buyer (not a current employee or director) for shares of Common Stock sold by the Company, from authorized but
unissued shares, as determined in good faith by its Board of Directors unless the Company shall become subject to a Merger Event, in which case the per share fair market value of Company Stock shall be deemed to be the per share value to be received
by the holders of the Company’s Company Stock pursuant to such Merger Event. 
 Upon partial exercise by either cash or Net Issuance, the Company shall
promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective
Date hereof. 
 (b) Exercise Prior to Expiration. To the extent this Agreement is not previously exercised as to all Company Stock
subject hereto, and if the fair market value of one share of the Company Stock is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even if not surrendered)
immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Company Stock upon such expiration shall be determined pursuant to Section 3(a). To the extent this Agreement or any portion
thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify Hercules of the number of shares of Company Stock, if any, Hercules is to receive by reason of such automatic exercise. 

SECTION 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Common Stock to provide for
the exercise of the rights to purchase Company Stock as provided for herein. 

  
 3 

 SECTION 5. NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the
Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 
 SECTION 6. NO RIGHTS AS
STOCKHOLDER. 
 This Agreement does not entitle Hercules to any voting rights or other rights as a stockholder of the Company prior to the exercise of this
Agreement. 
 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Hercules’s initial address, for purposes
of such registry, is set forth in Section 12(g). Hercules may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 
 The
Exercise Price and the number of shares of Company Stock purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger
Event. If at any time a Merger Event shall occur, then, as a part of such Merger Event, lawful provision shall be made so that Hercules shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of capital
stock or other securities or property (collectively, “Reference Property”) that Hercules would have received in connection with such Merger Event if Hercules had exercised this Agreement immediately prior to the Merger Event. In any
such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Agreement with respect to the rights and interests of Hercules after the Merger Event
to the end that the provisions of this Agreement (including adjustments of the Exercise Price and adjustments to ensure that the provisions of this Section 8 shall thereafter be applicable, as nearly as possible, to the purchase rights under
this Agreement in relation to any Reference Property thereafter acquirable upon exercise of such purchase rights) shall continue to be applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing, in connection
with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Agreement; provided that if the Reference Property includes shares of stock or other securities and assets of an entity other
than the successor or purchasing company, as the case may be, in such Merger Event, then such other entity shall assume the obligations under this Agreement and any such assumption shall contain such additional provisions to protect the interests of
Hercules as reasonably necessary by reason of the foregoing (as determined in good faith by the Company’s Board of Directors). In connection with a Merger Event and upon Hercules’s written election to the Company, the Company shall cause
this Warrant Agreement to be exchanged for the consideration that Hercules would have received if Hercules had chosen to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Warrant Agreement without actually
exercising such right, acquiring such shares and exchanging such shares for such consideration. The provisions of this Section 8(a) shall similarly apply to successive Merger Events. 

(b) Reclassification of Shares. Except for Merger Events subject to Section 8(a), and subject to Section 8(f), if the Company
at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of any
other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase
rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. The provisions of this Section 8(b) shall similarly apply to successive combination, reclassification, exchange,
subdivision or other change. 

  
 4 

 (c) Subdivision or Combination of Shares. If the Company at any time shall combine or
subdivide its Company Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately decreased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased. 

(d) Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: 

(i) pay a dividend with respect to the Company Stock payable in Company Stock, then the Exercise Price shall be adjusted, from
and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the
numerator of which shall be the total number of shares of Company Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Company Stock outstanding
immediately after such dividend or distribution; or 
 (ii) make any other distribution with respect to Company Stock, except
any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that Hercules shall receive upon exercise or conversion of this Warrant a proportionate share
of any such distribution as though it were the holder of the Company Stock as of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution. 

(e) Antidilution Rights. Additional antidilution rights applicable to the Company Stock purchasable hereunder are as set forth in the
Charter and shall be applicable with respect to the Company Stock issuable hereunder. The Company shall promptly provide Hercules with any restatement, amendment, modification or waiver of the Charter; provided, that no such amendment,
modification or waiver shall impair or reduce the antidilution rights applicable to the Company Stock as of the date hereof unless such amendment, modification or waiver affects the rights of Hercules with respect to the Company Stock subject to
this Warrant in the same manner as it affects all of the outstanding shares of Company Stock. The Company shall provide Hercules with prior written notice of any issuance of its stock or other equity security to occur after the Effective Date of
this Agreement that could trigger the antidilution rights provided in the Charter, which notice shall include (a) the price at which such stock or security is to be sold, (b) the number of shares to be issued, and (c) such other
information as necessary for Hercules to determine if a dilutive event has occurred. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment pursuant to this subsection (e), the forgoing subsection (d) and the Charter.

 (f) Notice of Adjustments. If: (i) the Company shall declare any dividend or distribution upon its stock, whether in stock,
cash, property or other securities (assuming Hercules consents to a dividend involving cash, property or other securities); (ii) the Company shall grant, issue or sell any Purchase Rights; (iii) there shall be any Merger Event;
(iv) the Company shall sell, lease, license or otherwise transfer all or substantially all of its assets; or (v) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event,
the Company shall send to Hercules: (A) at least ten (10) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend, distribution, subscription rights (specifying
the date on which the holders of Company Stock shall be entitled thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; and (B) in the case of any such Merger Event, sale, lease,
license or other transfer of all or substantially all assets, dissolution, liquidation or winding up, at least ten (10) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of
Company Stock shall be entitled to exchange their Company Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding up). 

  
 5 

 Each such written notice shall set forth, in reasonable detail, (i) the event requiring the notice, and
(ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the
number of shares subject to purchase hereunder after giving effect to such adjustment, and shall be given in accordance with Section 12(g) below. 

(g) Timely Notice. Failure to timely provide such notice required by subsection (f) above shall entitle Hercules to retain the
benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Hercules. For purposes of this subsection (g), and notwithstanding anything to the contrary in Section 12(g),
the notice period shall begin on the date Hercules actually receives a written notice containing all the information required to be provided in such subsection (g). 

SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

(a) Reservation of Company Stock. The Company Stock issuable upon exercise of Hercules’s rights has been duly and validly reserved
and, when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Company
Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws. The Company has made available to Hercules true, correct and complete copies of its Charter and current bylaws. The
issuance of certificates (or book-entry form equivalent) for shares of Company Stock upon exercise of this Agreement shall be made without charge to Hercules for any issuance tax in respect thereof, or other cost incurred by the Company in
connection with such exercise and the related issuance of shares of Company Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any
certificate (or book-entry form equivalent) in a name other than that of Hercules. 
 (b) Due Authority. The execution and delivery
by the Company of this Agreement and the performance of all obligations of the Company hereunder, including the issuance to Hercules of the right to acquire the shares of Company Stock have been duly authorized by all necessary corporate action on
the part of the Company. This Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation or order applicable to it; and (3) does not contravene any
provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in
accordance with its terms. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or
taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except for the filing
of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby. 

(d) Issued Securities. All issued and outstanding shares of, Company Stock or any other securities of the Company have been duly
authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Company Stock and any other securities were issued in full compliance with all federal and state securities laws. In addition, as of the date immediately
preceding the date of this Agreement: 
 (i) The authorized capital of the Company consists of (A) 100,000,000 shares of
Common Stock, of which 11,943,618 shares are issued and outstanding, and (B) 5,000,000 shares of Preferred Stock, $0.0001 par value per share, no shares of which are issued and outstanding. 

  
 6 

 (ii) The Company has reserved 1,966,027 shares of Common Stock for issuance under
its Stock Option Plan(s), under which options to purchase 722,215 shares of Common Stock are outstanding. There are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any
authorized but unissued shares of the Company’s capital stock or other securities of the Company, except for the Warrant Agreement dated as of June 3, 2014 between the Company and Hercules. The Company has no outstanding loans to any
employee, officer or director of the Company. 
 (iii) In accordance with the Company’s Charter, no stockholder of the
Company has preemptive rights to purchase new issuances of the Company’s capital stock. 
 (e) Insurance. The Company has in
full force and effect insurance policies, with extended coverage, insuring the Company and its property and business against such losses and risks, and in such amounts, as are customary for corporations engaged in a similar business and similarly
situated and as otherwise may be required pursuant to the terms of any other contract or agreement. 
 (f) Registration of Shares.
The Company shall, subject to receipt of necessary information from Hercules, either (i) prepare and file with the SEC, on or prior to the 30th calendar day following the date on which the Company becomes eligible to use a Form S-3 registration
statement to register the Common Stock issuable on exercise of this Agreement, a registration statement on Form S-3 to enable the Company to issue to Hercules upon exercise of this Agreement registered and freely tradable shares of Common Stock or
to enable the resale by Hercules on a delayed or continuous basis under Rule 415 of the Act of the shares of Common Stock issued to Hercules upon exercise of this Agreement (the “S-3 Registration Statement”), and use its commercially
reasonable efforts to cause the Registration Statement to become effective within 60 calendar days after the date by which the Registration Statement shall have been required to be filed in accordance with this Section 9(f), or
(ii) include the Common Stock issuable on exercise of this Agreement in the next Form S-1 registration statement, if any, that the Company elects to file (the “S-1 Registration Statement”) should such registration statement be filed
prior to the date when the S-3 Registration Statement is required to be filed; provided, however, that (x) the Company shall not be required to include in the S-1 Registration Statement any of the Common Stock issuable on exercise of this
Agreement unless, in the case that the S-1 Registration Statement relates to an offering involving an underwriting of shares of Common Stock to be issued by the Company, Hercules accepts the terms of the underwriting as agreed upon between the
Company and its underwriters, and (y) if in connection with any such underwritten offering the managing underwriter imposes a limitation on the number of shares of Common Stock which may be included in the S-1 Registration Statement because in
the judgment of the managing underwriter such limitation is necessary to effect an orderly public distribution, and such limitation is imposed pro rata with respect to any shares of Common Stock whose holders have a contractual, incidental right to
include such Common Stock in the S-1 Registration Statement, and there is first excluded from the S-1 Registration Statement all shares of Common Stock sought to be included therein by (1) any holder thereof not having any such contractual,
incidental registration rights, and (2) any holder thereof having contractual, incidental registration rights subordinate and junior to the rights of Hercules, then the Company shall be obligated to include in such S-1 Registration Statement
only such limited portion (which may be none) of the shares of Common Stock issuable upon exercise of this Agreement. 
 (g) Exempt
Transaction. Subject to the accuracy of Hercules’s representations in Section 10, the issuance of the Company Stock upon exercise of this Agreement will constitute a transaction exempt from (i) the registration requirements of
Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws. 

(h) Compliance with Rule 144. Provided that the Company is then subject to the reporting requirements of Section 13(a) or 15(d) of
the 1934 Act, the Company shall use its best efforts to comply with all applicable reporting requirements under paragraph (c)(1) of Rule 144 until such time as either the S-1 Registration Statement or S-3 Registration Statement becomes effective. If
Hercules proposes 

  
 7 

 
to sell Company Stock issuable upon the exercise of this Agreement in compliance with Rule 144, then, upon Hercules’s written request to the Company, the Company shall furnish to Hercules,
within three business days after receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in paragraph (c)(1) of Rule 144, as such Rule may be amended from time to
time, and shall, upon receipt from Hercules of an appropriate Rule 144 stockholder representation letter and any other documents reasonably requested by the Company, issue appropriate instructions to its transfer agent to remove the restrictive
legend regarding the Act from any certificates (or book-entry form equivalent) evidencing the Common Stock issuable upon the exercise of this Agreement. No opinion of counsel will be required for sales made pursuant to Rule 144. 

(i) Information Rights. At any time while this Agreement is outstanding or Hercules holds shares of Company Stock acquired under this
Agreement, if (and then for only so long as) the Company is either (i) not subject to SEC reporting obligations under Section 13(a) or Section 15(d) of the 1934 Act, or (ii) is not timely in meeting such SEC reporting obligations
(after giving effect to extensions pursuant to Rule 12b-25(b)), then Hercules shall be entitled to the information rights contained in Sections 7.1 of the Loan Agreement; provided, however, that the Company shall not be required to deliver a
Compliance Certificate once all Secured Obligations (as defined in the Loan Agreement) owed by the Company to Hercules have been repaid. 

(j) Listing of Shares. The Common Stock is listed for trading on the NASDAQ Capital Market under the symbol “ZSAN” as of the
Effective Date. 
 SECTION 10. REPRESENTATIONS AND COVENANTS OF HERCULES. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of Hercules: 

(a) Investment Purpose. The right to acquire Company Stock is being acquired for investment and not with a view to the sale or
distribution of any part thereof, and Hercules has no present intention of selling or engaging in any public distribution of such rights or the Company Stock except pursuant to an effective registration statement or an exemption from the
registration requirements of the Act. 
 (b) Private Issue. Hercules understands (i) that the Company Stock issuable upon
exercise of this Agreement is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and qualifications requirements
thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 

(c) Financial Risk. Hercules has such knowledge and experience in financial and business matters as to be capable of evaluating the
merits and risks of its investment, and has the ability to bear the economic risks of its investment. 
 (d) Reserved. 

(e) Accredited Investor. Hercules is an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of
Regulation D, as presently in effect. 
 (f) No Short Sales. The holder of this Agreement has not engaged, and will not engage, in
“short sales” of the Company Stock as long as this Agreement is exercisable into shares of Company Stock. The term “short sale” shall mean any sale of a security which the seller does not own or any sale which is consummated by
the delivery of a security borrowed by, or for the account of, the seller. 
 SECTION 11. TRANSFERS. 

Subject to compliance with applicable federal and state securities laws this Agreement and all rights hereunder are transferable, in whole or in part, without
charge to the holder hereof (except for transfer taxes) 

  
 8 

 
upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when endorsed in blank, shall
be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with this Agreement as the
absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer
in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company receives
such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. 
 SECTION 12. MISCELLANEOUS.

 (a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had
been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. 

(b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by
suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Hercules will not have an adequate remedy at law and where
damages will not be readily ascertainable. The Company expressly agrees that it shall not oppose an application by Hercules or any other person entitled to the benefit of this Agreement requiring specific performance of any or all provisions hereof
or enjoining the Company from continuing to commit any such breach of this Agreement. 
 (c) No Impairment of Rights. The Company
will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the
taking of all such actions as may be necessary or appropriate in order to protect the rights of Hercules against impairment. 
 (d)
Additional Documents. The Company, upon execution of this Agreement, shall provide Hercules with certified resolutions with respect to the Company’s entry into this Agreement, the reservation of shares for issuance upon exercise of this
Agreement, and issuance of shares upon exercise of this Agreement. The Company shall also supply to Hercules upon its request documentation reasonably necessary to evaluate whether to exercise (in cash or a net issuance basis) this Agreement,
including without limitation, (i) any merger/purchase/asset sale agreement and related documents and estimated payout allocations to each of the respective shareholders, warrant and option holders in connection with a Merger Event,
(ii) the most recent capitalization tables, 409A valuations (if any), and board determination of share value (including any waterfall or per share allocations provided to the stockholders), and (iii) most recent Charter. 

(e) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and Hercules relating hereto, the
prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(e), attorneys’ fees shall include without limitation fees
incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and
third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. 

(f) Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or
unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the
intention of the parties underlying the invalid, illegal or unenforceable provision. 

  
 9 

 (g) Notices. Except as otherwise provided herein, any notice, demand, request, consent,
approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served,
given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery if transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the recipient, or, if transmission or
delivery occurs on a non-business day or after such time, the first business day thereafter, or the first business day after deposit with an overnight express service or overnight mail delivery service; or (ii) the third calendar day after
deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows: 
 If to
Hercules: 
 HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 

Legal Department 
 Attention:
Chief Legal Officer and Manuel Henriquez 
 400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301 
 Facsimile:
650-473-9194 
 Telephone: 650-289-3060 

With a copy (which shall not constitute notice) to: 

Steven O. Gasser 
 PremierCounsel
LLP 
 49 Stevenson Street, 4th Floor 

San Francisco, CA 94105 

Facsimile: 415-357-1414 

Telephone: 415-357-1400 
  

	(i)	If to the Company: 

 Zosano Pharma Corporation 

Attention: Vikram Lamba 
 34790
Ardentech Court 
 Fremont, CA 94555 

Facsimile: 
 Telephone: 

With a copy (which shall not constitute notice) to: 

Jeffrey L. Quillen 
 Foley Hoag
LLP 
 155 Seaport Blvd. 

Boston, MA 02210 
 Facsimile:
617-832-7000 
 Telephone: 617-832-1205 
 or to
such other address as each party may designate for itself by like notice. 
 (h) Entire Agreement; Amendments. This Agreement
constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements,
whether written or oral, with respect to the subject matter hereof (including Hercules’s proposal letter dated May 27, 2015). None of the terms of this Agreement may be amended except by an instrument executed by each of the parties
hereto. 

  
 10 

 (i) Headings. The various headings in this Agreement are inserted for convenience only and
shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 
 (j) Advice of Counsel. Each of the
parties represents to each other party hereto that it has discussed (or had an opportunity to discuss) with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p), 12(q) and 12(r). 

(k) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement. 
 (l) No Waiver. No omission or delay by Hercules at any time to enforce any right
or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which Hercules is entitled, nor shall it in any way
affect the right of Hercules to enforce such provisions thereafter. 
 (m) Survival. All agreements, representations and warranties
contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Hercules and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 

(n) Governing Law. This Agreement has been negotiated and delivered to Hercules in the State of California, and shall have been
accepted by Hercules in the State of California. Delivery of Company Stock to Hercules by the Company under this Agreement is due in the State of California. This Agreement shall be governed by, and construed and enforced in accordance with, the
laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

(o) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any
state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County,
State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and
(d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance
with the requirements for notice set forth in Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall
limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 (p) Mutual Waiver of Jury Trial.
Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration
rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND HERCULES SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM,
COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST HERCULES OR ITS ASSIGNEE OR BY HERCULES OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including
Claims that involve Persons other than the Company and Hercules; Claims that arise out of or are in any way connected to the relationship between the Company and Hercules; and any Claims for damages, breach of contract, specific performance, or any
equitable or legal relief of any kind, arising out of this Agreement. 

  
 11 

 (q) Judicial Reference. If the waiver of jury trial set forth above is ineffective or
unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to California Code of Civil Procedure Section 638, et seq., before a mutually acceptable referee or, if the
parties cannot agree, a referee selected by the Presiding Judge of Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding.

 (r) Prejudgment Relief. In the event Claims are to be resolved by judicial reference to a private judge, either party may seek
from a court of competent jurisdiction identified in Section 12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all
Claims are otherwise subject to resolution by judicial reference. 
 (s) Counterparts. This Agreement and any amendments, waivers,
consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but
one and the same instrument. 
 (t) Specific Performance. The parties hereto hereby declare that it is impossible to measure in money
the damages which will accrue to Hercules by reason of the Company’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable by Hercules. If Hercules institutes
any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that Hercules has an adequate remedy at law, and such person shall not
offer in any such action or proceeding the claim or defense that such remedy at law exists. 
 [Remainder of Page Intentionally Left Blank]

  
 12 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its officers thereunto duly
authorized as of the Effective Date. 
  

							
	        COMPANY:				Zosano Pharma Corporation
				
					By:		 /s/ Vikram Lamba

					Name: Vikram Lamba
					Title: CEO
			
	        HERCULES:				HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
					By:		 /s/ Ben Bang

					Name: Ben Bang
					Title: Associate General Counsel

  
 13 

 EXHIBIT I 

NOTICE OF EXERCISE 
  

	To:	[                                    
            ] 

  

	(1)	The undersigned Hercules hereby elects to purchase [                    ] shares of the Common Stock of Zosano
Pharma Corporation pursuant to the terms of the Agreement dated the [        ] day of [                ,
            ] (the “Agreement”) between
[                                ] and Hercules, and [CASH PAYMENT: tenders
herewith payment of the Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

 

	(2)	Please issue a certificate or certificates representing said shares of Common Stock (or book-entry form equivalent) in the name of the undersigned or in such other name as is specified below. 

 

							
					  

					(Name)
			
					  

					(Address)
			
	        Hercules:				 HERCULES TECHNOLOGY
 GROWTH
CAPITAL, INC.

				
					By:		  

					Name: Ben Bang
					Title: Associate General Counsel

  
 14 

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The undersigned
[                                         
                               ], hereby acknowledge receipt of the “Notice of
Exercise” from Hercules Technology Growth Capital, Inc. to purchase [                    ] shares of the Common Stock of Zosano Pharma
Corporation pursuant to the terms of the Agreement, and further acknowledges that [                    ] shares remain subject to purchase
under the terms of the Agreement. 
  

							
	        COMPANY:				Zosano Pharma Corporation
				
					By:		  

				
					Title:		  

				
					Date:		  

  
 15 

 EXHIBIT III 

TRANSFER NOTICE 
 (To transfer or assign the
foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing
Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

			
	  

	(Please Print)
		
	whose address is	 	  

	
	  

		 	

  

			
	Dated:	 	  

		
	Holder’s Signature:	 	  

		
	Holder’s Address:	 	  

	
	  

 Signature
Guaranteed:                                       
                                         
                                        

NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without alteration or enlargement
or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 

  
 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]